There is conflicting data regarding the penetrance and clinical significance of RAD50 germline PVs and BC risk; there is very little likely association, apparently the attention of current studies is being directed especially on the somatic PVs of the RAD 50 gene, implicated in modulation prognosis and sensitivity to platinum drugs and PARP1 [67]. The gene discussed is PARP1; the disease is breast cancer.